Search Results - "Gilham, David Edward"

CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity by Kueberuwa, Gray, Kalaitsidou, Milena, Cheadle, Eleanor, Hawkins, Robert Edward, Gilham, David Edward

“…Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer therapy. Larger studies have shown ∼90% complete remission rates…”
Get full text

Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells by Gilham, David Edward, Bornschein, Simon, Springuel, Lorraine, Michaux, Alexandre, Steklov, Mikhail, Breman, Eytan, Sotiropoulou, Panagiota A

“…Abstract only 3103 Background: Engineered T cells expressing chimeric antigen receptors (CAR) are now delivering clinically relevant results in patients with…”
Get full text

CAR T-cell therapy: toxicity and the relevance of preclinical models by Kalaitsidou, Milena, Kueberuwa, Gray, Schütt, Antje, Gilham, David Edward

“…Chimeric antigen receptor (CAR) T cells form part of a broad wave of immunotherapies that are showing promise in early phase cancer clinical trials. This…”
Get full text

Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC by Prenen, Hans, Dekervel, Jeroen, Hendlisz, Alain, Anguille, Sébastien, Awada, Ahmad, Cerf, Emilie, Lonez, Caroline, Breman, Eytan, Dheur, Marie-Sophie, Alcantar-Orozco, Erik, Gilham, David Edward, Flament, Anne, Lehmann, Frederic, Van Cutsem, Eric

“…Abstract only 74 Background: CYAD-101 is a first-in-class, non-gene edited allogeneic CAR T-cell product that combines the broad breadth of tumor targeting of…”
Get full text

CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy by Prenen, Hans, Dekervel, Jeroen, Anguille, Sébastien, Hendlisz, Alain, Michaux, Alexandre, Sotiropoulou, Panagiota A, Gilham, David Edward, Mauen, Sébastien, Snykers, Sarah, Cerf, Emilie, Lonez, Caroline, Flament, Anne, Lehmann, Frederic, Van Cutsem, Eric

“…Abstract only 3032 Background: In contrast to autologous CAR-T cell therapies, allogeneic donor-derived CAR-T cells can be banked and used in a timely fashion…”
Get full text

Development of an allogeneic product by CAR-T cells TCR knock-down by Raitano, Susanna, Bornschein, Simon, Bolsée, Jennifer, Marijsse, Jérôme, Marchand, Céline, Huberty, Fanny, Violle, Benjamin, N'Guyen, Thuy, Jacques-Hespel, Céline, Ramelot, Nancy, Houssa, Julien, Agaugue, Sophie, Gilham, David Edward

“…Abstract only…”
Get full text

A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types by Verma, Bikash, Aftimos, Philippe Georges, Awada, Ahmad, Machiels, Jean-Pascal H., Brayer, Jason B., Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Lonez, Caroline, Gilham, David Edward, Lehmann, Frederic

“…Abstract only TPS3093 Background: Chimeric Antigen Receptor (CAR)-T therapy has potentially serious limitations related to target antigen loss, toxicity due to…”
Get full text

TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach by Gilham, David Edward, Michaux, Alexandre, Breman, Eytan, Mauen, Sébastien, Bolsée, Jennifer, Huberty, Fanny, Marijsse, Jérôme, Violle, Benjamin, Jacques-Hespel, Céline, Marchand, Céline, Ramelot, Nancy, N'Guyen, Thuy, Houssa, Julien, Agaugue, Sophie

“…Abstract only…”
Get full text

Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015 by Gilham, David Edward, Anderson, John, Bridgeman, John Stephen, Hawkins, Robert Edward, Exley, Mark Adrian, Stauss, Hans, Maher, John, Pule, Martin, Sewell, Andrew Kelvin, Bendle, Gavin, Lee, Steven, Qasim, Waseem, Thrasher, Adrian, Morris, Emma

“…Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this…”
Get more information

CCR7 + selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo by Kueberuwa, Gray, Gornall, Hannah, Alcantar-Orozco, Erik Marcelo, Bouvier, Deborah, Kapacee, Zainul Abedin, Hawkins, Robert Edward, Gilham, David Edward

“…Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T…”
Get full text